The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hypothyroxinemia as a goal in cancer management by triiodothyronine (T3) substitution for supplemental L-thyroxine (T4) and T3 modulated hypothyroxinemia: Outcomes in a compassionate care population.
A. Hercbergs
No relevant relationships to disclose
O. Ashur -Fabian
No relevant relationships to disclose